GlobeNewsWire · LGVN · October 26, 2026

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Get the app for more

Explore stock news, insights and company research.